Stockreport

Travere Therapeutics Reports First Quarter 2024 Financial Results

Travere Therapeutics, Inc.  (TVTX) 
PDF FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target acti [Read more]